(Q42627615)

4 November 2017

Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin (English)

1 reference

4 November 2017

coronary artery disease

1 reference

John S Sampalis

1

1 reference

4 November 2017

Stéphane Bissonnette

2

1 reference

4 November 2017

Rafik Habib

3

1 reference

4 November 2017

Stella Boukas

4

1 reference

4 November 2017

Ezetrol Add-On Investigators

5

1 reference

4 November 2017

language of work or name

English

0 references

publication date

31 July 2007

1 reference

Annals of Pharmacotherapy

4 November 2017

1 reference

4 November 2017

41

1 reference

4 November 2017

9

1 reference

4 November 2017

1345-1351

1 reference

Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events

4 November 2017

1 reference

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

21 January 2018

1 reference

Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals

21 January 2018

1 reference

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

21 January 2018

1 reference

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

An updated coronary risk profile. A statement for health professionals.

21 January 2018

1 reference

Application of the updated Framingham risk score to Japanese men.

21 January 2018

1 reference

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

21 January 2018

1 reference

Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On St

21 January 2018

1 reference

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia.

21 January 2018

1 reference

The Framingham prediction rule is not valid in a European population of treated hypertensive patients

21 January 2018

1 reference

Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study

21 January 2018

1 reference

Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1K140

1 reference

4 November 2017

1 reference